FLX Bio Secures $50,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4d2ca368-e7f1-4849-b6c5-5739d5c23634 - Date
4/30/2016 - Company Name
FLX Bio - Mailing Address
561 Eccles Avenue South San Francisco, CA 94080 USA - Company Description
Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. - Website
http://www.flxbio.com - Transaction Type
Venture Equity - Transaction Amount
$50,000,000 - Transaction Round
Series B - Proceeds Purposes
The funds will be used to support further discovery and development of its pipeline of novel immuno-oncology compounds and to advance development of the company’s Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia. - M&A Terms
- Venture Investor
The Column Group - Venture Investor
Topspin Partners - Venture Investor
Kleiner Perkins Caufield & Byers - Venture Investor
Celgene
